John Young is recorded as Analyst at Canaccord and CFO at Ambarella Inc (AMBA). Ambarella Inc reported in an 8-K filed October 18, 2023 that John Young was appointed Chief Financial Officer, effective February 1, 2024. The proxy statement of Ambarella Inc reports total compensation of $2,489,328 for John Young in fiscal 2026, including a base salary of $310,440. Disclosed compensation is on record for 4 fiscal years. John Young has spoken on 18 earnings calls and 3 other investor events across 8 companies, most recently for iRhythm Holdings, Inc. on November 5, 2026. Those appearances were for Ambarella Inc (AMBA), Pulmonx Corp (LUNG), Staar Surgical Co (STAA), iRhythm Holdings, Inc. (IRTC), AtriCure, Inc. (ATRC) and 3 other companies. Ambarella Inc is classified in the Semiconductor Equipment & Materials industry within the Technology sector. Pfizer Inc is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other companies whose calls John Young spoke on are classified in the Healthcare sector. Other leadership on record at Ambarella Inc includes John A. Young (CFO), Chan Lee (COO), Leslie Kohn (CTO and Board Member) and 7 others.
“John Young, the Company's current Vice President of Finance, has been elected to succeed Mr. White as Chief Financial Officer effective as of February 1, 2024.”
Ambarella Inc Form 8-K, filed October 18, 2023
· Read the filing
John Young on recent calls
“I want to ask a question just on the guidance changes here. You know, looking at the organic guidance, excluding the $16 million, if I'm asked is right, it looks like Q4 organic growth is in quiet 10% to 12% versus the 14.9% or so this quarter.”
“You know, the pain management franchise grew solid again this quarter. How much of the revenue this quarter came from new accounts versus deeper use in existing accounts, and has Cernonomy or CryoXP reached a meaningful share of revenue yet?”
“You know, just to start on the U.S. business, you know, Q3 beat the seasonality you usually see in the U.S. growing sequentially. Any way you could parse out where this growth came from in the U.S. in terms of DTC efforts, the ramping productivity, the reps, anything you could quantify there would be great.”
“I'll now review the financial highlights for the second quarter, fiscal year 2027, ending July 31, 2026. I will also provide a financial outlook for our third quarter of fiscal year 2027, ending October 31, 2026.”
